Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease

NCT00664599 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Behcet's Syndrome

Interventions

DRUG: Rituximab
DRUG: Cytotoxic Combination

Sponsor

Tehran University of Medical Sciences

Collaborators

[object Object]